June 6, 2022 7:57am
How now, brown cow, a barrel of beer analogy; what’s on tap for the week – more volatility
Pre-open indications: 4 Upside Indications, 2 Downside Indications, 2 Sell into Strength, 1 Puff/Pump/Promote
RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
The 8;00 A.M., ET edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.70% (+261 points), S&P futures are UP +1.04% (+42 points) and NASDAQ futures are UP +1.39% (+174 points) early in the pre-open – so far,
Stock futures were higher in early morning trading Monday looking to a positive open,
European stocks were also higher,
Asia-Pacific stocks were mixed as a private survey showed another contraction in China’s service sector activity for May.
Henry’omics:
U.S. stocks slid Friday to close the week lower as investors digested a stronger-than-expected jobs report and its implication for monetary policy going forward.
The Dow fell 348.58 points, or 1.1%, to 32,899.70. The S&P 500 slipped 1.6% to 4,108.54 and the Nasdaq fell nearly 2.5% to 12,012.73.
RegMed Investors’ (RMi) closing bell: “when you wish upon a share price. Luck enhanced a Friday positive sector spiral with mostly low percentage “moves” side-by-side low negative “dives”. I never leave investors uninformed” … https://www.regmedinvestors.com/articles/12459
Ebb and flow –
Q2/22 –
June – 2 positive and 1 negative close
· May - 11 positive and 10 negative closes
· April - 1 holiday, 6 positive and 13 negative closes
Q1/22:
· March – 13 negative and 10 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes
RegMed Investors (RMi) - Q1/22 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Exhibiting positive indication:
BioLife Solutions (BLFS) closed down -$0.40 to $13.76 after Thursday’s +$0.80, Wednesday’s -$0.36 and Tuesday’s +$1.60 with a positive +$0.68 or +4.94% pre-open indication,
Fate Therapeutics (FATE) closed up+$0.29 to $23.65 after Thursday’s +$0.73 <52-week low of $20.49>, Wednesday’s $22.63 and Tuesday’s $23.11 following the previous Friday’s $23.58 with a positive +$0.45 or +1.90% pre-open indication,
Intellia Therapeutics (NTLA) closed up +$0.64 to $45.31 after Thursday’s +$1.81, Wednesday’s -$3.28, Tuesday’s -$2.61 with a positive +$0.21 or +0.46% pre-open indication,
Editas Medicine (EDIT) closed up +$0.37 to $11.91 after Thursday’s +$0.57, Wednesday’s -$0.42 and Tuesday’s -$0.29 with a positive +$0.02 or +0.17% pre-open indication,
Exhibiting negative indications:
Sage Therapeutics (SAGE) closed up +$0.22 to $36.93 after Thursday’s +$2.47, Wednesday’s +$2.97 and Tuesday’s -$0.97 with a negative -$0.93 or -2.52% pre-open indication following its shares rising +15.6% last week having met its primary endpoints in a P3 study to treat women with postpartum depression,
UniQure NV (QURE) closed up +$0.28 to $14.95 after Thursday’s +$0.51 <52-week low of $12.52>, Wednesday’s $14.16 and Tuesday’s $14.36 following the previous Friday’s $14.90 with a negative -$0.45 or -3.01% pre-open indication,
Sell into Strength:
Global Blood Therapeutics (GBT) closed up +$1.10 to $26.11 after Thursday’s +$0.99 <52-week low of $22.67>, Wednesday’s -$0.92 and Tuesday’s -$1.21 with a positive +$0.04 or +0.15% pre-market indication,
Chinook Therapeutics (KDNY) closed up +$1.41 to $17.43 after Thursday’s -$1.41, Wednesday’s -$1.39 and Tuesday’s -$0.45 with positive +$0.02 or +0.11% following Friday’s aftermarket indication,
Puff/Pump and Promote: Maintaining SELL
Biostage (OTCQB: BSTG) closed down -$0.33 to $4.45 with 250 shares traded after Thursday’s flat with 1 share traded, Wednesday’s -$0.37 to $4.75 with 100 shares traded, Tuesday’s -$0.22 with 330 shares traded having traded with six (6 – May 20 to May 27) sessions being flat.
- WARNING: Earnings reported a VERY SAD picture of a company’s status without U.S investors and reliance on non-U.S. Chinese investors. Another PPM -private placement – this one for $5.1 M without a price per share notification. Also, the terminal death lawsuit just got settled (4/28) for $6 M with a PPM – a preferred convertible debt financing. is it the ONLY avenue to finance utilizing non-U.S. Chinese investors?
· So, Has BSTG filed its Annual Report to the FDA, isn’t it a “Material Fact”?
The BOTTOM LINE: The cell and gene therapy sector last week suffered and celebrated and I believe a bit of a “reckoning” is due …:
· Friday ending with a positive close of 27/8.
· Thursday ending with a positive close of 28/6 and 1 flat.
· Wednesday ending with a negative close of 6/29 and 1 flat.
· Tuesday ending with a negative close of 7/28.
· Monday was a market holiday
Again, as have I written (repeatedly), “There's a battle in the cell and gene therapy sector between which or what breaks first: share pricing resilience or tumbling into yet another downturn as fear remains beneath the strength of any positive close” …
I am not always right but, more than frequently not wrong … I just DO NOT trust this market … too much fear and panic. This continuing state of volatility confirms fears that I have been expressing in these daily and weekly posts.
What changes …
I have NOT seen ANY step-up of declining company investment by ANY CEOs and their management teams – WHY NOT?
I try to keep it simple … and short!
I caution investors that the severe share pricing’s – technical and fundamental damage has been suffered these past several months which will take longer than a few good sessions to repair.
Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
